NASDAQ: VRDNViridian Therapeutics Inc Stock
$22.92-0.04 (-0.17%)
Updated Sep 4, 2026
VRDN Price
$22.92
Fair Value Price
-$10.74
Market Cap
$2.60B
52 Week Low
$13.19
52 Week High
$34.29
P/E
-6.76x
P/B
3.92x
P/S
27.86x
PEG
N/A
Dividend Yield
N/A
Revenue
$71.13M
Earnings
-$386.97M
Gross Margin
100%
Operating Margin
-522.11%
Profit Margin
-544.1%
Debt to Equity
0.66
Operating Cash Flow
-$333M
Beta
0.96
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
VRDN Overview
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VRDN's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -12.86% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VRDN
Ranked#421 of 458
Ranked#421 of 458
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.55 | A | |
| $111.62 | A | |
| $7.10 | A |
Be the first to know about important VRDN news, forecast changes, insider trades & much more!
VRDN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VRDN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VRDN ($22.92) is overvalued by 313.46% relative to our estimate of its Fair Value price of -$10.74 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VRDN ($22.92) is not significantly undervalued (313.46%) relative to our estimate of its Fair Value price of -$10.74 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VRDN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VRDN due diligence checks available for Premium users.
Valuation
VRDN fair value
Fair Value of VRDN stock based on Discounted Cash Flow (DCF)
Price
$22.92
Fair Value
-$10.74
Undervalued by
313.46%
VRDN ($22.92) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VRDN ($22.92) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VRDN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VRDN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.76x
Industry
10.49x
Market
40.73x
VRDN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.92x
Industry
5.57x
VRDN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VRDN's financial health
Profit margin
Revenue
$284.0k
Net Income
-$127.1M
Profit Margin
-44,760.2%
VRDN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
VRDN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.1B
Liabilities
$435.1M
Debt to equity
0.66
VRDN's short-term assets ($1.08B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VRDN's short-term assets ($1.08B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VRDN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
VRDN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$105.3M
Investing
-$231.2M
Financing
$325.1M
VRDN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VRDN vs Biotech Stocks
Viridian Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.